Mycoplasma Testing Market Share, Size, Trends, Opportunity and Forecast 2024-2032

IMARC Group, a leading market research company, has recently releases report titled “Mycoplasma Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2032,” The study provides a detailed analysis of the industry, including the global mycoplasma testing market share, size, trends, and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.

Report Highlights:

How big is the mycoplasma testing market?

The global mycoplasma testing market size reached US$ 914.9 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 2,388.2 Million by 2032, exhibiting a growth rate (CAGR) of 11.25% during 2024-2032.

Factors Affecting the Growth of the Mycoplasma Testing Industry:

• Increasing Demand for Biopharmaceuticals:

The escalating demand for biopharmaceuticals, which include vaccines, monoclonal antibodies, and cell therapy products for the treatment of various diseases, is one of the major factors boosting the market growth. Moreover, the imposition of stringent regulatory guidelines for mycoplasma testing in biopharmaceutical production processes to provide safety and quality to the products is acting as a growth-inducing factor. In addition to this, the increasing investment in advanced mycoplasma testing solutions to adhere to regulatory standards, maintain product integrity, and mitigate the risk of contamination is propelling the market growth. Furthermore, the burgeoning prevalence of chronic diseases and the growing geriatric population, escalating the demand for innovative and effective treatment options, is amplifying the market growth.

• Rapid Technological Advancements in Mycoplasma Detection:

The rising technological advancements in mycoplasma detection methods, such as the development of rapid, sensitive, and reliable testing technologies, are contributing to the market growth. In line with this, the introduction of polymerase chain reaction (PCR) based assays in mycoplasma detection, owing to their high sensitivity, specificity, and rapid turnaround time, is fostering the market growth. PCR assays can detect mycoplasma contamination in a matter of hours, as opposed to the days or weeks required by culture-based methods, enabling timely decision-making in biopharmaceutical production processes. Moreover, the advent of advanced molecular techniques, such as real-time PCR and next-generation sequencing (NGS), to enhance the capability to identify and quantify mycoplasma contamination with unprecedented accuracy is catalyzing the market growth.

• Expansion of the Biotechnology Industry:

The widespread expansion of the biotechnology industry, including drug discovery and development, cell and gene therapy, and the production of recombinant proteins and vaccines, is positively impacting the market growth. Along with this, the increasing investment in research and development (R&D), rising healthcare needs, and the continuous search for novel therapeutics and diagnostics are boosting the market growth. Moreover, the growing need for stringent quality control measures to ensure the absence of contaminants, including mycoplasma, which can affect the safety and effectiveness of biotechnological products, is fueling the market growth. Additionally, the heightened globalization of the biotechnology industry that fosters collaborations and partnerships between academic institutions, research organizations, and biopharmaceutical companies, leading to innovations in mycoplasma testing methodologies, is favoring the market growth.

Request for a sample copy of this report: https://www.imarcgroup.com/mycoplasma-testing-market/requestsample

What are the growth prospects and trends in the mycoplasma testing industry?

The increasing emphasis on the quality and safety of biopharmaceutical products represents one of the key factors driving the market growth. Regulatory agencies have set stringent guidelines for the absence of mycoplasma in final products, propelling the 

What is included in market segmentation?

The report has segmented the market into the following categories:

Breakup by Product: 

• Instruments
• Kits and Reagents
• Services

Kits and reagents constituted the largest segment due to their widespread use in routine mycoplasma testing across various applications, offering ease of use, consistency, and reliability in results.

Breakup by Technology:

• NAAT (Nucleic Acid Amplification Technique)
• ELISA (Enzyme-linked Immunoassay)
• DNA Staining
• Others

On the basis of technology, the market has been divided into NAAT (Nucleic Acid Amplification Technique), ELISA (Enzyme-linked Immunoassay), DNA staining, and others. 

Breakup by Application:

• Cell Line Testing
• Virus Testing
• End of Production Cells Testing
• Others

Cell line testing represented the largest segment, attributed to the critical need for ensuring cell culture purity in biopharmaceutical manufacturing and research settings.

Breakup by End User:

• Academic Research Institutes
• Cell Banks
• Contract Research Organizations
• Pharmaceutical and Biotechnology Companies
• Others

Pharmaceutical and biotechnology companies accounted for the largest market share, driven by the implementation of stringent regulatory requirements to conduct mycoplasma testing to ensure the safety and efficacy of biopharmaceutical products before market release.

Market Breakup by Region:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America's dominance in the mycoplasma testing market is attributed to the region’s robust biopharmaceutical industry, stringent regulatory standards, and the presence of leading pharmaceutical and biotechnology companies that demand advanced mycoplasma testing solutions.

Who are the key players operating in the industry?

The report covers the major market players including:

• ATCC
• Bionique Testing Laboratories Inc. (Asahi Kasei Medical Co. Ltd.)
• Bio-Rad Laboratories Inc.
• Charles River Laboratories International Inc.
• Eurofins Scientific SE
• Invivogen
• Lonza Group
• Merck KGaA
• Roche Holding AG
• Sartorius AG
• Thermo Fisher Scientific Inc.

Browse the full report with TOC and List of Figures: https://www.imarcgroup.com/mycoplasma-testing-market

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact US:

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Email: sales@imarcgroup.com

LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/